In this March 16, 2020, file photo, a subject receives a shot in the first-stage safety study clinical trial of a potential vaccine by Moderna for COVID-19, the disease caused by the new coronavirus, at the Kaiser Permanente Washington Health Research Institute in Seattle.
Ted S. Warren | AP
An analyst at Goldman Sachs thinks a coronavirus vaccine could be approved before year-end by the U.S. as the country tries to stem a massive uptick in cases.
Data compiled by Johns Hopkins University showed U.S. cases grew by a staggering 77,200 — shattering a one-day record. Cases are rising in nearly every state as authorities roll back social distancing measures. California, Florida and Texas are some of the hardest-hit states recently. On Thursday alone, they combined for more than 38,000 cases.
The virus' rapid spread has led the U.S. government to fast track the development of a potential vaccine, leading Goldman analyst Salveen Richter to believe "a vaccine may gain US approval in 2H20."
Below are some companies highlighted by Goldman Sachs that could get a vaccine candidate approved later this year.
"later" - Google News
July 18, 2020 at 12:46AM
https://ift.tt/3ezb1Te
Goldman Sachs says a coronavirus vaccine could be approved later in 2020 - CNBC
"later" - Google News
https://ift.tt/2KR2wq4
Bagikan Berita Ini
0 Response to "Goldman Sachs says a coronavirus vaccine could be approved later in 2020 - CNBC"
Post a Comment